SCHEDULE: BlackRock Reports 8.3% Stake in Core Laboratories

BlackRock, Inc. has updated its Schedule 13G filing, disclosing beneficial ownership of 8.3% of Core Laboratories Inc.'s common stock as of July 31, 2026.

Summary

• BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 3,811,390 shares of Core Laboratories Inc. common stock.
• This represents 8.3% of the class of securities outstanding as of July 31, 2026.
• BlackRock holds sole voting power for 3,703,577 shares and sole dispositive power for 3,811,390 shares.
• The filing clarifies that this ownership is held by various business units of BlackRock, Inc. and its subsidiaries and affiliates.
• No single person's interest in the common stock exceeds five percent.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership rather than a reflection of new company performance or strategy.

Positives

• BlackRock, a significant institutional investor, maintains a substantial stake, indicating continued confidence or investment strategy.
• The filing confirms that no single entity holds an excessive percentage of shares, suggesting a diversified shareholder base.

Negatives

• The filing does not contain any new financial performance data or strategic updates for Core Laboratories Inc.

Risks

• Concentration of ownership, even if diversified across BlackRock entities, could lead to significant influence on company decisions.
• Changes in BlackRock's investment strategy could lead to substantial buying or selling pressure on Core Laboratories Inc. stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Core Laboratories Inc.'s future performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock of Core Laboratories Inc. No one person's interest in the common stock of Core Laboratories Inc is more than five percent of the total outstanding common shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine for large institutional investors like BlackRock, indicating their role as passive investors in many public companies. This filing confirms BlackRock's significant, but not controlling, stake in Core Laboratories Inc., a company operating in the oilfield services sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can influence market perception and trading activity. The passive nature of the filing suggests no immediate intent to influence control.
• Management: BlackRock's stake is substantial enough to warrant attention from management, though the filing indicates no intent to control.
• Creditors: No direct impact is indicated, as the filing pertains to equity ownership.

Next Steps

• BlackRock will continue to monitor its beneficial ownership of Core Laboratories Inc. common stock and file amendments to Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Core Laboratories Inc, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Ownership Stake